“The Adept program is coming by the end of the year as we guided.”

In context

“o go as you said, Amiparantha. Amiparantha I'm very happy because what I have seen is Phase III conducting and enrolling patients that are very similar to what we have seen in two. And you remember in Phase II, had a very good reduction of the risk of decline of FVC. Sixty percent in IPF and more than seventy percent in So IPF is coming this year, is closer. Actually, we'd be very, very closer compared to what we guided before. So this is very exciting. Very high medical need. Maldexygen, I think Christopher Boerner already spoke about. Stroke has already been derisked in my view from the data we will see in few hours. There is no reason to believe that we will have a different, if not better, outcome. And the AFib, the confidence is all there. Then I would not underestimate that program. The Adept program is coming by the end of the year as we guided. We are on track. All of this is moving at pace. So as you said, four different therapeutic areas where we'll have a major readout and these are very transformative regimen. Adam Lenkowsky, you want to? Adam Lenkowsky: I think, and you covered it extremely well. Why don't we go to the next? Thank you. Thank you. Operator: Our next question today comes from Christopher Schott at JPMorgan. Please go ahead. Christopher Schott: Great. Thanks very much. Just two for me. First, just elaborate on Eliquis dynamics for 2026 contributing to growth this year. Maybe just a bigger picture one on business development priorities. Just elaborate a little bit more terms of your focus right now. Is this more on deepening presence in existing therapeutic areas? Or maybe pursuing more corona-like kind of expa”